Acorda Therapeutics Inc. (ACOR)
Россия
  • Россия
  • Украина

Acorda Therapeutics Inc. (ACOR)

Contact Details

420 Saw Mill River Rd, Ardsley, New York, USA 10502-2605
(914) 347-4300
420 Saw Mill River Rd, Ardsley, New York, USA 10502-2605

General Information

Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company`s lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

Contact Information

Phone(914) 347-4300
Fax(914) 347-4560
Twitter@AcordaNews
Thomson Reuters PermID4295909042

Products

Drug NameCondition
AMPYRAMultiple sclerosis

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
President and CEO$4,045,18120143.2%
CFO$1,295,0662014-70.2%
General Counsel, Divisional President and Secretary$2,334,28220148.1%
Chief Medical Officer$1,663,69920142.8%
Other Executive Officer$5,167,6662014

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
Department of Veterans AffairsChemical and Pharmaceutical Products Manufacturing Machinery, Chemicals, Drugs and Biologicals, Medical and Surgical Instruments, Equipment and SuppliesJuly 28, 2011$12 million
Department of Veterans AffairsDrugs and Biologicals, Medical and Surgical Instruments, Equipment and SuppliesOctober 01, 2011$6.83 million
Department of Veterans AffairsDrugs and Biologicals, Medical and Surgical Instruments, Equipment and SuppliesApril 06, 2011$295,390.50
Department of Veterans AffairsDrugs and Biologicals, Medical and Surgical Instruments, Equipment and SuppliesNovember 04, 2010$219,493.35
Department of Veterans AffairsDrugs and Biologicals, Drugs and Biologicals, Veterinary UseJanuary 01, 2005$41,996.10

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing
  • Research and Development in Biotechnology
  • Biological Product (except Diagnostic) Manufacturing

SIC Industries

  • Drugs Acting On The Central Nervous System & Sense Organs
  • Biotechnical Research, Commercial
  • Biological Products, Except Diagnostic

Company Size

Sales Volume$493 million
Employees535

Ownership

Ticker SymbolACOR
ExchangeNASDAQ Global Select Market
Type of EntityFor Profit Organization
Type of OrganizationFederally Funded Research and Development (R&D) Corporation
Type of OwnershipNot Tax Exempt Corporate Entity
State of IncorporationDelaware
Year Founded1995

Stocks

Previous Close27.66
Open27.86
Bid27.41 x 700
Ask27.42 x 2,400
Day`s Range27.26 - 28.06
52-Week Range25.38 - 43.25
Average Volume (1M)1,229,388
Trailing P/E67.46x
Beta1.46x
Market Cap.$1,265.42 Million
Last Dividend Amount0
1y Target Price Est.41.33

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue130,903148,199113,70799,851
Cost of Revenue26,55924,90022,86718,605
Gross Profit104,344123,29990,84081,246
Research Development43,98843,35631,22930,636
Selling General and Administrative52,98651,05652,81948,769
Depreciation and Amortization----
Other Operating Expenses3,5003,2001,1003,100
Total Operating Expenses127,033122,512108,015101,110
Other Income/Expenses Net----
Earnings Before Interest and Taxes3,87025,6875,692(1,259)
Interest Expense3,3744,0374,0104,051
Income Before Tax65421,7112,127(5,123)
Income Tax Expense(8,551)17,7701,130(2,038)
Minority Interest----
Net Income from Continuing Ops9,2053,941997(3,085)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income9,2053,941997(3,085)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares9,2053,941997(3,085)